{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:24:01Z","timestamp":1782440641391,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12149-024-01960-2","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T13:02:08Z","timestamp":1721307728000},"page":"884-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative post-therapeutic dosimetry between 2D planar-based and hybrid-based methods for personalized Lu-177 treatment"],"prefix":"10.1007","volume":"38","author":[{"given":"Wuri","family":"Handayani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maythinee","family":"Chantadisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benchamat","family":"Phromphao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nut","family":"Noipinit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panya","family":"Pasawang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-2829","authenticated-orcid":false,"given":"Kitiwat","family":"Khamwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"1960_CR1","unstructured":"National Research Council (US) and Institute of Medicine (US) Committee on State of the Science of Nuclear Medicine. Advancing Nuclear Medicine Through Innovation. Washington (DC): National Academies Press (US); 2007."},{"issue":"10","key":"1960_CR2","first-page":"560","volume":"35","author":"FR Vogenberg","year":"2010","unstructured":"Vogenberg FR, Barash CI, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. P T. 2010;35(10):560\u201376.","journal-title":"P T"},{"issue":"1","key":"1960_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/1874471008666150313114644","volume":"9","author":"T Das","year":"2016","unstructured":"Das T, Banerjee S. Theranostic applications of lutetium-177 in radionuclide therapy. Curr Radiopharm. 2016;9(1):94\u2013101.","journal-title":"Curr Radiopharm"},{"issue":"1","key":"1960_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jmrs.227","volume":"64","author":"L Emmett","year":"2017","unstructured":"Emmett L, et al. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52\u201360.","journal-title":"J Med Radiat Sci"},{"issue":"4","key":"1960_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.prro.2022.02.002","volume":"12","author":"AY Jia","year":"2022","unstructured":"Jia AY, et al. Lutetium-177 DOTATATE: a practical review. Pract Radiat Oncol. 2022;12(4):305\u201311.","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"1960_CR6","first-page":"205","volume":"55","author":"L Strigari","year":"2011","unstructured":"Strigari L, et al. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q J Nucl Med Mol Imaging. 2011;55(2):205\u201321.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"1","key":"1960_CR7","first-page":"5","volume":"55","author":"M Bardies","year":"2011","unstructured":"Bardies M, Buvat I. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry? Q J Nucl Med Mol Imaging. 2011;55(1):5\u201320.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"11","key":"1960_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187570","volume":"12","author":"D Kupitz","year":"2017","unstructured":"Kupitz D, et al. Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios. PLoS ONE. 2017;12(11): e0187570.","journal-title":"PLoS ONE"},{"issue":"1","key":"1960_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40658-021-00385-4","volume":"8","author":"F Rosar","year":"2021","unstructured":"Rosar F, et al. Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys. 2021;8(1):40.","journal-title":"EJNMMI Phys"},{"issue":"11","key":"1960_CR10","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s12149-021-01659-8","volume":"35","author":"K Chatachot","year":"2021","unstructured":"Chatachot K, Shiratori S, Chaiwatanarat T, Khamwan K. Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand. Ann Nucl Med. 2021;35(11):1193\u2013202.","journal-title":"Ann Nucl Med"},{"key":"1960_CR11","unstructured":"Sorenson JA. Methods for quantitating radioactivity, in vivo, by external counting measurements. 1971, University of Wisconsin--Madison. p. v, 126 leaves."},{"issue":"04","key":"1960_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1118\/1.594287","volume":"03","author":"SR Thomas","year":"1976","unstructured":"Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;03(04):253\u20135.","journal-title":"Med Phys"},{"key":"1960_CR13","unstructured":"Software HM. Hybrid Viewer Dosimetry Handbook. Vol. 5.1. 2020."},{"issue":"3","key":"1960_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, et al. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384.","journal-title":"J Nucl Med"},{"issue":"16","key":"1960_CR15","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/aad47a","volume":"63","author":"K Khamwan","year":"2018","unstructured":"Khamwan K, O\u2019Reilly SE, Plyku D, Goodkind A, Josefsson A, Cao X, Fahey FH, Treves ST, Bolch WE, Sgouros G. Re-evaluation of pediatric 18F-FDG dosimetry: Cristy-Eckerman versus UF\/NCI hybrid computational phantoms. Phys Med Biol. 2018;63(16): 165012.","journal-title":"Phys Med Biol"},{"key":"1960_CR16","doi-asserted-by":"crossref","unstructured":"Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP, 2002;32(3\u20134):5\u2013265.","DOI":"10.1016\/S0146-6453(03)00002-2"},{"key":"1960_CR17","doi-asserted-by":"crossref","unstructured":"Kamaldeep, et al. Examining absorbed doses of indigenously developed (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients at baseline and during course of peptide receptor radioligand therapy. Cancer Biother Radiopharm 2021;36(3):292\u2013304.","DOI":"10.1089\/cbr.2020.3640"},{"key":"1960_CR18","volume":"158","author":"ML Belli","year":"2020","unstructured":"Belli ML, et al. A whole body dosimetry protocol for peptide-receptor radionuclide therapy (PRRT): 2D planar image and hybrid 2D+3D SPECT\/CT image methods. J Vis Exp. 2020;158: e60477.","journal-title":"J Vis Exp"},{"issue":"3","key":"1960_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11307-016-0942-0","volume":"18","author":"M Hohberg","year":"2016","unstructured":"Hohberg M, et al. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [(177)Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016;18(3):437\u201345.","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"1960_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1960_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517\u201323.","journal-title":"J Nucl Med"},{"issue":"4","key":"1960_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/biomedicines4040025","volume":"4","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Gleisner KS. Personalized dosimetry for radionuclide therapy using molecular imaging tools. Biomedicines. 2016;4(4):25.","journal-title":"Biomedicines"},{"issue":"6","key":"1960_CR23","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"KS Gleisner","year":"2022","unstructured":"Gleisner KS, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1960_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejmp.2018.11.001","volume":"56","author":"G Marin","year":"2018","unstructured":"Marin G, et al. A dosimetry procedure for organs-at-risk in (177)Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Phys Med. 2018;56:41\u20139.","journal-title":"Phys Med"},{"issue":"1","key":"1960_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-018-0232-9","volume":"5","author":"KP Willowson","year":"2018","unstructured":"Willowson KP, et al. Feasibility and accuracy of single time point imaging for renal dosimetry following (177)Lu-DOTATATE (\u2018Lutate\u2019) therapy. EJNMMI Phys. 2018;5(1):33.","journal-title":"EJNMMI Phys"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01960-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-024-01960-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01960-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T17:15:21Z","timestamp":1729530921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-024-01960-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1960"],"URL":"https:\/\/doi.org\/10.1007\/s12149-024-01960-2","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}